This study provides mechanistic insights into energy reprogramming that permits myocardial dysfunction, and thus provides a proof of concept for antienergy reprogramming therapy for Dox‐induced cardiomyopathy through directly modulating G6P–AP‐1–Sln axis. This evidence concerns the gene SLN and cardiomyopathy.